Cargando…

Treatment outcomes of drug resistant tuberculosis patients with multiple poor prognostic indicators in Uganda: A countrywide 5-year retrospective study

BACKGROUND: Comorbid conditions and adverse drug events are associated with poor treatment outcomes among patients with drug resistant tuberculosis (DR – TB). This study aimed at determining the treatment outcomes of DR – TB patients with poor prognostic indicators in Uganda. METHODS: We reviewed tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Baluku, Joseph Baruch, Nakazibwe, Bridget, Naloka, Joshua, Nabwana, Martin, Mwanja, Sarah, Mulwana, Rose, Sempiira, Mike, Nassozi, Sylvia, Babirye, Febronius, Namugenyi, Carol, Ntambi, Samuel, Namiiro, Sharon, Bongomin, Felix, Katuramu, Richard, Andia-Biraro, Irene, Worodria, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856462/
https://www.ncbi.nlm.nih.gov/pubmed/33553682
http://dx.doi.org/10.1016/j.jctube.2021.100221
_version_ 1783646255088402432
author Baluku, Joseph Baruch
Nakazibwe, Bridget
Naloka, Joshua
Nabwana, Martin
Mwanja, Sarah
Mulwana, Rose
Sempiira, Mike
Nassozi, Sylvia
Babirye, Febronius
Namugenyi, Carol
Ntambi, Samuel
Namiiro, Sharon
Bongomin, Felix
Katuramu, Richard
Andia-Biraro, Irene
Worodria, William
author_facet Baluku, Joseph Baruch
Nakazibwe, Bridget
Naloka, Joshua
Nabwana, Martin
Mwanja, Sarah
Mulwana, Rose
Sempiira, Mike
Nassozi, Sylvia
Babirye, Febronius
Namugenyi, Carol
Ntambi, Samuel
Namiiro, Sharon
Bongomin, Felix
Katuramu, Richard
Andia-Biraro, Irene
Worodria, William
author_sort Baluku, Joseph Baruch
collection PubMed
description BACKGROUND: Comorbid conditions and adverse drug events are associated with poor treatment outcomes among patients with drug resistant tuberculosis (DR – TB). This study aimed at determining the treatment outcomes of DR – TB patients with poor prognostic indicators in Uganda. METHODS: We reviewed treatment records of DR – TB patients from 16 treatment sites in Uganda. Eligible patients had confirmed DR – TB, a treatment outcome in 2014–2019 and at least one of 15 pre-defined poor prognostic indicators at treatment initiation or during therapy. The pre-defined poor prognostic indicators were HIV co-infection, diabetes, heart failure, malignancy, psychiatric illness/symptoms, severe anaemia, alcohol use, cigarette smoking, low body mass index, elevated creatinine, hepatic dysfunction, hearing loss, resistance to fluoroquinolones and/or second-line aminoglycosides, previous exposure to second-line drugs (SLDs), and pregnancy. Tuberculosis treatment outcomes were treatment success, mortality, loss to follow up, and treatment failure as defined by the World Health Organisation. We used logistic and cox proportional hazards regression analysis to determine predictors of treatment success and mortality, respectively. RESULTS: Of 1122 DR – TB patients, 709 (63.2%) were male and the median (interquartile range, IQR) age was 36.0 (28.0–45.0) years. A total of 925 (82.4%) had ≥2 poor prognostic indicators. Treatment success and mortality occurred among 806 (71.8%) and 207 (18.4%) patients whereas treatment loss-to-follow-up and failure were observed among 96 (8.6%) and 13 (1.2%) patients, respectively. Mild (OR: 0.57, 95% CI 0.39–0.84, p = 0.004), moderate (OR: 0.18, 95% CI 0.12–0.26, p < 0.001) and severe anaemia (OR: 0.09, 95% CI 0.05–0.17, p < 0.001) and previous exposure to SLDs (OR: 0.19, 95% CI 0.08–0.48, p < 0.001) predicted lower odds of treatment success while the number of poor prognostic indicators (HR: 1.62, 95% CI 1.30–2.01, p < 0.001), for every additional poor prognostic indicator) predicted mortality. CONCLUSION: Among DR – TB patients with multiple poor prognostic indicators, mortality was the most frequent unsuccessful outcomes. Every additional poor prognostic indicator increased the risk of mortality while anaemia and previous exposure to SLDs were associated with lower odds of treatment success. The management of anaemia among DR – TB patients needs to be evaluated by prospective studies. DR – TB programs should also optimise DR – TB treatment the first time it is initiated.
format Online
Article
Text
id pubmed-7856462
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78564622021-02-05 Treatment outcomes of drug resistant tuberculosis patients with multiple poor prognostic indicators in Uganda: A countrywide 5-year retrospective study Baluku, Joseph Baruch Nakazibwe, Bridget Naloka, Joshua Nabwana, Martin Mwanja, Sarah Mulwana, Rose Sempiira, Mike Nassozi, Sylvia Babirye, Febronius Namugenyi, Carol Ntambi, Samuel Namiiro, Sharon Bongomin, Felix Katuramu, Richard Andia-Biraro, Irene Worodria, William J Clin Tuberc Other Mycobact Dis Article BACKGROUND: Comorbid conditions and adverse drug events are associated with poor treatment outcomes among patients with drug resistant tuberculosis (DR – TB). This study aimed at determining the treatment outcomes of DR – TB patients with poor prognostic indicators in Uganda. METHODS: We reviewed treatment records of DR – TB patients from 16 treatment sites in Uganda. Eligible patients had confirmed DR – TB, a treatment outcome in 2014–2019 and at least one of 15 pre-defined poor prognostic indicators at treatment initiation or during therapy. The pre-defined poor prognostic indicators were HIV co-infection, diabetes, heart failure, malignancy, psychiatric illness/symptoms, severe anaemia, alcohol use, cigarette smoking, low body mass index, elevated creatinine, hepatic dysfunction, hearing loss, resistance to fluoroquinolones and/or second-line aminoglycosides, previous exposure to second-line drugs (SLDs), and pregnancy. Tuberculosis treatment outcomes were treatment success, mortality, loss to follow up, and treatment failure as defined by the World Health Organisation. We used logistic and cox proportional hazards regression analysis to determine predictors of treatment success and mortality, respectively. RESULTS: Of 1122 DR – TB patients, 709 (63.2%) were male and the median (interquartile range, IQR) age was 36.0 (28.0–45.0) years. A total of 925 (82.4%) had ≥2 poor prognostic indicators. Treatment success and mortality occurred among 806 (71.8%) and 207 (18.4%) patients whereas treatment loss-to-follow-up and failure were observed among 96 (8.6%) and 13 (1.2%) patients, respectively. Mild (OR: 0.57, 95% CI 0.39–0.84, p = 0.004), moderate (OR: 0.18, 95% CI 0.12–0.26, p < 0.001) and severe anaemia (OR: 0.09, 95% CI 0.05–0.17, p < 0.001) and previous exposure to SLDs (OR: 0.19, 95% CI 0.08–0.48, p < 0.001) predicted lower odds of treatment success while the number of poor prognostic indicators (HR: 1.62, 95% CI 1.30–2.01, p < 0.001), for every additional poor prognostic indicator) predicted mortality. CONCLUSION: Among DR – TB patients with multiple poor prognostic indicators, mortality was the most frequent unsuccessful outcomes. Every additional poor prognostic indicator increased the risk of mortality while anaemia and previous exposure to SLDs were associated with lower odds of treatment success. The management of anaemia among DR – TB patients needs to be evaluated by prospective studies. DR – TB programs should also optimise DR – TB treatment the first time it is initiated. Elsevier 2021-01-27 /pmc/articles/PMC7856462/ /pubmed/33553682 http://dx.doi.org/10.1016/j.jctube.2021.100221 Text en © 2021 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Baluku, Joseph Baruch
Nakazibwe, Bridget
Naloka, Joshua
Nabwana, Martin
Mwanja, Sarah
Mulwana, Rose
Sempiira, Mike
Nassozi, Sylvia
Babirye, Febronius
Namugenyi, Carol
Ntambi, Samuel
Namiiro, Sharon
Bongomin, Felix
Katuramu, Richard
Andia-Biraro, Irene
Worodria, William
Treatment outcomes of drug resistant tuberculosis patients with multiple poor prognostic indicators in Uganda: A countrywide 5-year retrospective study
title Treatment outcomes of drug resistant tuberculosis patients with multiple poor prognostic indicators in Uganda: A countrywide 5-year retrospective study
title_full Treatment outcomes of drug resistant tuberculosis patients with multiple poor prognostic indicators in Uganda: A countrywide 5-year retrospective study
title_fullStr Treatment outcomes of drug resistant tuberculosis patients with multiple poor prognostic indicators in Uganda: A countrywide 5-year retrospective study
title_full_unstemmed Treatment outcomes of drug resistant tuberculosis patients with multiple poor prognostic indicators in Uganda: A countrywide 5-year retrospective study
title_short Treatment outcomes of drug resistant tuberculosis patients with multiple poor prognostic indicators in Uganda: A countrywide 5-year retrospective study
title_sort treatment outcomes of drug resistant tuberculosis patients with multiple poor prognostic indicators in uganda: a countrywide 5-year retrospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856462/
https://www.ncbi.nlm.nih.gov/pubmed/33553682
http://dx.doi.org/10.1016/j.jctube.2021.100221
work_keys_str_mv AT balukujosephbaruch treatmentoutcomesofdrugresistanttuberculosispatientswithmultiplepoorprognosticindicatorsinugandaacountrywide5yearretrospectivestudy
AT nakazibwebridget treatmentoutcomesofdrugresistanttuberculosispatientswithmultiplepoorprognosticindicatorsinugandaacountrywide5yearretrospectivestudy
AT nalokajoshua treatmentoutcomesofdrugresistanttuberculosispatientswithmultiplepoorprognosticindicatorsinugandaacountrywide5yearretrospectivestudy
AT nabwanamartin treatmentoutcomesofdrugresistanttuberculosispatientswithmultiplepoorprognosticindicatorsinugandaacountrywide5yearretrospectivestudy
AT mwanjasarah treatmentoutcomesofdrugresistanttuberculosispatientswithmultiplepoorprognosticindicatorsinugandaacountrywide5yearretrospectivestudy
AT mulwanarose treatmentoutcomesofdrugresistanttuberculosispatientswithmultiplepoorprognosticindicatorsinugandaacountrywide5yearretrospectivestudy
AT sempiiramike treatmentoutcomesofdrugresistanttuberculosispatientswithmultiplepoorprognosticindicatorsinugandaacountrywide5yearretrospectivestudy
AT nassozisylvia treatmentoutcomesofdrugresistanttuberculosispatientswithmultiplepoorprognosticindicatorsinugandaacountrywide5yearretrospectivestudy
AT babiryefebronius treatmentoutcomesofdrugresistanttuberculosispatientswithmultiplepoorprognosticindicatorsinugandaacountrywide5yearretrospectivestudy
AT namugenyicarol treatmentoutcomesofdrugresistanttuberculosispatientswithmultiplepoorprognosticindicatorsinugandaacountrywide5yearretrospectivestudy
AT ntambisamuel treatmentoutcomesofdrugresistanttuberculosispatientswithmultiplepoorprognosticindicatorsinugandaacountrywide5yearretrospectivestudy
AT namiirosharon treatmentoutcomesofdrugresistanttuberculosispatientswithmultiplepoorprognosticindicatorsinugandaacountrywide5yearretrospectivestudy
AT bongominfelix treatmentoutcomesofdrugresistanttuberculosispatientswithmultiplepoorprognosticindicatorsinugandaacountrywide5yearretrospectivestudy
AT katuramurichard treatmentoutcomesofdrugresistanttuberculosispatientswithmultiplepoorprognosticindicatorsinugandaacountrywide5yearretrospectivestudy
AT andiabiraroirene treatmentoutcomesofdrugresistanttuberculosispatientswithmultiplepoorprognosticindicatorsinugandaacountrywide5yearretrospectivestudy
AT worodriawilliam treatmentoutcomesofdrugresistanttuberculosispatientswithmultiplepoorprognosticindicatorsinugandaacountrywide5yearretrospectivestudy